Targeting of acivicin prodrugs as antibody conjugates

Journal of Controlled Release

Volumn 74, Issue 1-3, 2001, Pages 255-257

  Antczak, C ^a,b   Bauvois, B ^b   Monneret, C ^a   Florent, J C ^a  

^a CNRS   (France)

^b INSTITUT CURIE   (France)

Author keywords

Gamma glutamyltranspeptidase; Immunoconjugate; Leukemia; Tumor targeting

Indexed keywords

4 NITROANILINE; ACIVICIN; ANTIBODY CONJUGATE; ESTERASE; GAMMA GLUTAMYLTRANSFERASE; MONOCLONAL ANTIBODY; PRODRUG;

ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG HYDROLYSIS; DRUG SENSITIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; VALIDATION PROCESS;

ANTIBIOTICS, ANTINEOPLASTIC; CARBAMATES; ESTERASES; GAMMA-GLUTAMYLTRANSFERASE; HYDROLYSIS; IMMUNOCONJUGATES; ISOXAZOLES; MODELS, CHEMICAL; PRODRUGS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0035816150     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(01)00327-3     Document Type: Conference Paper

References (3)

1. Ectopeptidases in pathophysiology
2. Gamma-glutamyltranspeptidase: Catalytic, structural and functional aspects
3. Inhibition of gamma-glutamyl-transpeptidase activity at the surface of human myeloid cells is correlated with macrophage maturation and transforming growth-factor-beta production